Underactive Thyroid and Mounjaro: Can You Get It on the NHS?

Why the NHS eligibility question is harder than it looks

The NHS route to tirzepatide runs through strict phased criteria set out in NICE's appraisal TA1026. Right now, NHS access requires a BMI of 40 or above alongside four or more of a defined set of five comorbidities: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. From around June 2026 a second cohort opened, covering BMI 35–39.9 with four or more of those same conditions. Hypothyroidism does not appear on that list. So even if weight gain from your thyroid condition is clinically real and well-documented, it does not move the needle on NHS eligibility by itself. That is a frustrating answer, and it is the honest one.

What sometimes changes the calculation is whether you also carry one or more of those listed conditions alongside your thyroid diagnosis. Many people with hypothyroidism do: dyslipidaemia and hypertension are both common in people whose thyroid is under-treated or intermittently controlled. If you think you might meet the broader NHS criteria, the right first step is a conversation with your GP. The NHS Mounjaro access pathway page has more detail on how those criteria apply in practice.

Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, reducing the relevant figure by 2.5 kg/m² for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. NICE TA1026 sets all of this out in full.

The levothyroxine absorption question your prescriber will ask

This is the part of the conversation most people haven't prepared for. Tirzepatide slows gastric emptying, which is part of how it reduces appetite. For most medicines, a slightly slower gut transit is not clinically significant. Levothyroxine is different. It has a narrow therapeutic window, is absorbed within a short time-frame in the upper small intestine, and its absorption is already highly sensitive to timing, food, and other oral medicines taken at the same time.

There is limited direct clinical evidence specifically on tirzepatide and levothyroxine co-administration, so this sits in the category of things that are plausible, biologically grounded, and not yet fully characterised. What that means practically: your prescriber cannot tell you that starting Mounjaro will destabilise your thyroid levels, and they cannot tell you it won't. They can say that thyroid function monitoring after starting treatment is prudent, and most endocrinologists would agree. The NHS tirzepatide medicines page is a useful reference for the side-effect and interaction profile, and the Mounjaro Summary of Product Characteristics on the eMC gives the prescriber-level detail.

If your thyroid levels have been stable on the same levothyroxine dose for a year or more, that is relevant context for your prescriber. If they fluctuate regularly, that is equally relevant. Either way, the decision is theirs to make, not yours to pre-empt.

When thyroid history is an outright contraindication

One thyroid-related situation is not a grey area. A personal or family history of medullary thyroid carcinoma, or a diagnosis of Multiple Endocrine Neoplasia type 2, means tirzepatide should not be used. This is stated clearly in the Mounjaro SmPC and applies to both NHS and private prescribing. A prescriber will screen for this as part of any Mounjaro consultation, and it is important to mention it unprompted if it applies to you or a close relative.

Common hypothyroidism treated with levothyroxine is a different matter entirely. It is not listed as a contraindication in the SmPC, and many people with well-managed underactive thyroids are assessed as suitable for tirzepatide through private clinics. Suitable, though, is a clinical judgement made by a prescriber reviewing your individual history, not a category decision based on the diagnosis alone. Our prescribers at nume review every consultation personally, the same day, without delegating that assessment to software.

Private access: what the process looks like if you decide to explore it

If your NHS route is blocked or the waiting list is long, private prescribing through a regulated online pharmacy is the alternative many people with hypothyroidism end up exploring. The process at a legitimate, GPhC-registered service starts with a free clinical consultation covering your full medical history, including thyroid diagnosis, current levothyroxine dose, and how stable your levels have been. Identity and current weight are verified before anything is prescribed.

If a prescriber approves treatment, orders placed before noon on a weekday are dispatched the same day. What arrives is a plain, unbranded box via DPD with tracking to your phone, containing the Mounjaro KwikPen itself, each pen delivering four weekly doses. Nothing about the packaging announces what's inside. Some patients also ask about buying Mounjaro directly from Eli Lilly, which is worth understanding as a separate route before deciding how to proceed. You can look into what Mounjaro costs privately before committing, and there are no subscription structures or automatic renewals: every repeat order goes through a fresh clinical review. If you want to understand what the broader treatment options look like alongside this, the treatment overview sets it out clearly.

The decision about whether to proceed belongs to you and your prescriber together, not to a checklist. For anyone with an underactive thyroid, the honest advice is: go in informed, mention your levothyroxine dose and how recently your levels were checked, and ask what monitoring your prescriber would recommend if treatment is approved. It is also worth knowing that if your BMI sits below 30, there is guidance on how to approach getting Mounjaro at a lower BMI, since the criteria and options differ from the standard pathway.